Feeds:
Posts
Comments

Posts Tagged ‘Immune-Oncology Drug Discovery’


Real Time Coverage @BIOConvention #BIO2019: Keynote: Siddhartha Mukherjee, Oncologist and Pulitzer Author; June 4 9AM Philadelphia PA

Reporter: Stephen J. Williams, PhD. @StephenJWillia2

 

Hematologist and oncologist Siddhartha Mukherjee was born in New Delhi, India. He holds a BS in biology from Stanford University, a DPhil in immunology from Oxford University (where he was a Rhodes Scholar), and an MD from Harvard Medical School. He completed his internal medicine residency and an oncology fellowship at Massachusetts General Hospital. Dr. Murkherjee is an assistant professor of medicine at Columbia University Medical Center. He lives in Manhattan with his wife, artist Sarah Sze, and their two daughters. His Pulitzer Prize-winning book, The Emperor of All Maladies: A Biography of Cancer, tells the story of cancer from its first description in an ancient Egyptian scroll to the gleaming laboratories of modern research institutions. A three-part documentary series based on the book, directed by Barak Goodman and executive produced by Ken Burns, debuts on PBS stations March 30 and continues on March 31 and April 1. The film interweaves a sweeping historical narrative with intimate stories about contemporary patients and an investigation into the latest scientific breakthroughs. He has also written the award winning book “The Gene: An Intimate History” and is Founder of Vor Biopharma, who had just published on their CD33 engineered hematopoetic stem cells as an immunooncology therapy VOR33.

Hon. James C. Greenwood- former Congressional representative and Founder CEO of BIO: moderator

Greenwood: Never have the threats from DC to innovation in the biotech field been so great.  Focused on some great recent innovations and successes in gene therapy.  Although the cost high, father of two LMR retinopathy patients said if his sons had to go through a lifetime of constant care it would cost much more than the gene therapy from Spark cost.  Politicians need to realize that medicines that completely cure diseases are worth much more.  They should meet in the middle with respect to developing a new payer model that will not hurt innovation.

Dr. Mukherjee:  He go into oncology from a virology PhD because he liked to understand the human aspect

of disease.  As an oncologist he gets to interact more closely with patients.  The oncology horizon is always changing.  He likened his view of oncology and cancer as a pyramid with prevention the base, then early detection then therapy at top.

We haven’t found preventable human carcinogens, none that is highly proven causal

This will be the next challenge for cancer researchers, to figure out why we can’t identify these preventable carcinogens.

 

 

 

 

Please follow on Twitter using these @ handles and # hashtags

@Handles

@DrSidMukherjee

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

 

Other Articles on this Open Access Journal on Interviews with Scientific Leaders Include:

Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders at https://www.amazon.com/dp/B078313281 – electronic Table of Contents

Jennifer Doudna and NPR science correspondent Joe Palca, several interviews

Practicing Oncology: Medscape Editor-in-Chief Eric J. Topol, MD interviews Siddhartha Mukherjee, MD, PhD

Eric Topol interviews Al Gore on Genomics and Privacy

Dr. Mercola Interviews Dr. Saul About Beta-Blockers

Volume Two: Medical Scientific Discoveries for the 21st Century & Interviews with Scientific Leaders

 

Read Full Post »


Juno Acquires AbVitro for $125M: high-throughput and single-cell sequencing capabilities for Immune-Oncology Drug Discovery, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 1: Next Generation Sequencing (NGS)

Juno Acquires AbVitro for $125M: high-throughput and single-cell sequencing capabilities for Immune-Oncology Drug Discovery

Reporter: Aviva Lev-Ari, PhD, RN

 

Luke Timmerman reported on 1/11/2016 in Forbes that

 

  • Seattle-based Juno is announcing today that it has agreed to acquire Boston-based AbVitro, a spinout from George Church’s lab at Harvard University, for about $125 million in cash and stock. Specifically, Juno is offering $78 million in cash and 1,289,193 shares of its stock (valued at $36.39 a share at Friday’s close).

 

  • The AbVitro technology will also become part of Juno’s broader collaboration with biotech giant Celgene CELG +0.88%. The big biotech has agreed in principle to license some of the technology that’s outside of Juno’s strategic zone. Essentially, Juno and Celgene operated like a joint scouting team. Rob Hershberg, Celgene’s new chief scientific officer, said in a statement: “Juno’s newly acquired high-throughput, single-cell sequencing capabilities have the potential to expand their current pipeline and Celgene is excited by the opportunity to access some of these potential new drugs.”

 

SOURCE

http://www.forbes.com/sites/luketimmerman/2016/01/11/juno-acquires-harvard-spinout-abvitro-for-125m-to-broaden-the-scope-of-cancer-immunotherapy/

 

Juno Agrees to Acquire AbVitro

January 11, 2016, 09:55:00 AM EDT By Dow Jones Business News
Juno Therapeutics Inc. agreed to acquire privately held biotechnology company AbVitro Inc. in a cash- and-stock deal valued at roughly $125 million and reached a preliminary deal with collaboration partner Celgene Corp. related to the acquisition.

Juno, which develops cancer treatments that use the body’s own immune system to fight the disease, said the deal includes $78 million in cash and roughly 1.3 million shares. Juno also said it plans to relocate AbVitro scientists to Seattle.

Juno, which went public in late 2014, said the acquisition of Boston-based AbVitro provides it with a next-generation single cell sequencing platform that increases its capabilities in T cell technologies, which ramp up the power of the cells to see and attack tumors.
Under the preliminary pact, Juno would license Celgene a subset of the acquired technology and grant Celgene options to certain related potential product rights.

Celgene agreed in June to pay Juno $150 million in upfront fees, and purchase 9.1 million or $846.3 million of newly issued shares, in exchange for certain options to market Juno’s experimental immunotherapy treatments. The companies were to initially focus on treatments Juno is developing that involve genetically engineering immune-system warriors called T cells to attack tumors, a strategy that has shown promise in treating leukemia and other cancers of the blood.

In an investor presentation, Juno said AbVitro’s technology will let it sift through millions of individual cells in a few hours to identify receptors that Juno’s immunity technology can attach to.

Juno is competing against Novartis AG and Kite Pharma to develop such cell therapy strategies.

Write to Tess Stynes at tess.stynes@wsj.com
(END) Dow Jones Newswires
01-11-160955ET
Copyright (c) 2016 Dow Jones & Company, Inc.
http://www.nasdaq.com/article/juno-agrees-to-acquire-abvitro-20160111-00716#ixzz3x3i4qL4S

Read Full Post »